The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Janssen
Research Funding - Janssen
IMAAGEN trial update: Effect of abiraterone acetate and low dose prednisone on PSA and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer.
 
E David Crawford
No Relationships to Disclose
 
Neal D. Shore
Consulting or Advisory Role - Janssen
Research Funding - Janssen
 
Willie Underwood
Consulting or Advisory Role - Janssen
Research Funding - Janssen
 
Anil Londhe
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
Research Funding - Janssen Research & Development
 
Shawn C. Black
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
Research Funding - Janssen
 
Tracy McGowan
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
Research Funding - Janssen
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Metamark Genetics
Consulting or Advisory Role - Amgen; Aragon Pharmaceuticals; Archimedes; Astellas Pharma; Auven Therapeutics; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Celgene; Dendreon; Endocyte; Exelixis; Genomic Health; GTx; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MTG Therapeutics; OncoCellMDX; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio; Teva; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Progenics; Sanofi